Archives of Pediatric Infectious Diseases

Published by: Kowsar

Treatment of Colchicine-Resistant Familial Mediterranean Fever With Anakinra

Vadood Javadi Parvaneh 1 and Reza Shiari 1 , *
Authors Information
1 Department of Pediatric Rheumatology, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Pediatric Infectious Diseases: July 01, 2015, 3 (3); e21664
  • Published Online: July 14, 2015
  • Article Type: Case Report
  • Received: July 1, 2014
  • Accepted: July 30, 2014
  • DOI: 10.5812/pedinfect.21664v2

To Cite: Javadi Parvaneh V, Shiari R. Treatment of Colchicine-Resistant Familial Mediterranean Fever With Anakinra, Arch Pediatr Infect Dis. 2015 ; 3(3):e21664. doi: 10.5812/pedinfect.21664v2.

Copyright © 2015, Pediartric Infections Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore). 1998; 77(4): 268-97[PubMed]
  • 2. Aksentijevich I, Torosyan Y, Samuels J, Centola M, Pras E, Chae JJ, et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet. 1999; 64(4): 949-62[PubMed]
  • 3. Stoffman N, Magal N, Shohat T, Lotan R, Koman S, Oron A, et al. Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet. 2000; 8(4): 307-10[DOI][PubMed]
  • 4. Gershoni-Baruch R, Shinawi M, Leah K, Badarnah K, Brik R. Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur J Hum Genet. 2001; 9(8): 634-7[DOI][PubMed]
  • 5. Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001; 9(7): 553-5[DOI][PubMed]
  • 6. Salehzadeh F, Emami D, Zolfegari AA, Yazdanbod A, Habibzadeh S, Bashardost B, et al. Familial Mediterranean fever in northwest of Iran (Ardabil): the first global report from Iran. Turk J Pediatr. 2008; 50(1): 40-4[PubMed]
  • 7. Farivar S, Shiari R, Hadi E. Molecular analysis of MEFV gene in Iranian children with Familial Mediterranean fever. Indian Journal of Rheumatology. 2010; 5(2): 66-8[DOI]
  • 8. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997; 90(4): 797-807[PubMed]
  • 9. A candidate gene for familial Mediterranean fever. Nat Genet. 1997; 17(1): 25-31[PubMed]
  • 10. Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of pediatric rheumatology. 2011;
  • 11. Tunca M, Akar S, Soyturk M, Kirkali G, Resmi H, Akhunlar H, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol. 2004; 22(4 Suppl 34)-40[PubMed]
  • 12. Seyahi E, Ozdogan H, Masatlioglu S, Yazici H. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clin Exp Rheumatol. 2002; 20(4 Suppl 26)-4[PubMed]
  • 13. Kataoka H, Kumagai H, Hanai H. Treating familial Mediterranean fever with prazosin hydrochloride. Ann Intern Med. 1998; 129(5): 424[PubMed]
  • 14. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol. 2007; 13(1): 38-40[DOI][PubMed]
  • 15. Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007; 119(2)-83[DOI][PubMed]
  • 16. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum. 1994; 37(12): 1804-11[PubMed]
  • 17. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008; 167(6): 695-6[DOI][PubMed]
  • 18. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006; 103(26): 9982-7[DOI][PubMed]
  • 19. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine. 2008; 75(4): 504-5[DOI][PubMed]
  • 20. Farivar S, Hassani M, Shiari R. Interleukin-1 as a Key Factor in the Development of Inflammatory Diseases. Arch Pediatr Infect Dis. 2014; 1(3)[DOI]
  • 21. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004; 364(9447): 1779-85[DOI][PubMed]
  • 22. Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis. 2007; 49(3): 477-81[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments